• 22 February 2017

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, today announces the successful dosing of the first patients in a Phase 1/2a proof of concept study in the US of TOP1630 ophthalmic solution for the treatment of dry eye syndrome (DES).

  • 6 February 2017

     Sonendo® Inc. today announced it has acquired PIPStek™ LLC, including all of the intellectual property for its PIPS® laser technologies.  PIPStek™ LLC will continue as a stand-alone company and will be a wholly owned subsidiary of Sonendo.

  • 1 February 2017

    InDex Pharmaceuticals Holding AB (publ) today announced that the company has entered an agreement for services with the global contract research organization (CRO) PAREXEL for the implementation of the CONDUCT study. CONDUCT is a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis.

  • 31 January 2017

    Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies, and Genkyotex, a privately-held Swiss biopharmaceutical company and the leader in NOX therapies, today announce that the information document (Document E) drawn up in relation to the planned strategic combination between the two companies announced on December 22, 2016 was registered with the French financial market authority (Autorité des Marchés Financiers - AMF) under reference number E.17-004 on January 31, 2017.

  • 24 January 2017

    Study to evaluate safety and efficacy of ASN100 in high-risk, mechanically ventilated ICU patients.